A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.
Dideoxyadenosine has been studied across 19 research domains including 🔬 Oncology, 🦴 Bone & Joint, 🔬 Inflammation, 🧠 Focus & Attention, 🧬 Hormones. The primary research focus is 🔬 Oncology with 12% of studies addressing this area.
The following compounds share molecular targets with Dideoxyadenosine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Dideoxyadenosine is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.